Table 2 Cox regression multivariate analysis for lung function parameters before allo-HCT and clinical parameters for bronchiolitis obliterans syndrome and death.

A.
Subdistribution hazard ratio for BOS incidence
	N	p value	SHR	95% CI
Conditioning with BuCy FluBu4 TBF MAC	175 29 37	– 0.08 0.77	1 0.28 1.11	– 0.07, 1.17 0.52, 2.40
TLC < 80% predicted	25	0.02	0.12	0.02, 0.71
FEV1 < median % of predicted (99%)	115	0.004	2.39	1.31, 4.35
In vivo T-cell depletion^a	110	0.001	0.29	0.16, 0.51
CMV patient positivity	134	0.014	2.11	1.16, 3.84

B.
Hazard ratio estimates for death
	n	p value	HR	95% CI
Conditioning with BuCy FluBu4 TBF MAC	175 29 37	– 0.17 0.76	1 0.60 0.92	– 0.29, 1.24 0.54, 1.55
FEV1 < 80% of predicted initial	31	0.005	2.01	1.23, 3.28
Disease status before allo-HCT^b - early - intermediate - late	113 15 111	– 0.56 0.001	1 0.75 2.53	– 0.29, 1.94 1.74, 3.68

Subdistribution hazard ratios (SHR) and confidence intervals (CI) for single pulmonary function test (PFT) values before allo-HCT and clinical parameters were estimated in multivariate analysis following backward selection for (A) BOS incidence using the Fine and Gray regression model in the presence of competing risks and for (B) overall survival using Cox regression proportional hazard ratio. Single PFT values and clinical parameters with a p value of 0.1 in univariate analysis were selected for the multivariate analysis. Conditioning was included as hypothesis variable. FEV1, forced vital capacity in 1 s. BuCy, Busulfan/Cyclophosphamide; FluBu4, Fludarabine/Busulfan 4 days; TBF MAC, Thiotepa/Busulfan/Fludarabine myeloablative conditioning.
^aIn vivo T-cell depletion includes patients receiving alemtuzumab and antithymocyte globuline (ATG).
^bDisease stage defined by EBMT score (Gratwohl et al., 2012).

Quick links

Search